We've entered a new era where we contemplate how to improve patients' quality of life
As pediatric brain tumor survival rates climb past two-thirds, medicine finds itself confronting a quieter, more enduring question: what kind of life awaits the child who is saved? In South Korea, a multi-institutional research team backed by a landmark Samsung donation is systematically tracking the cognitive, emotional, and physical toll that life-saving treatments leave on young survivors — building, for the first time, a structured pathway from diagnosis to rehabilitation. The effort reflects a broader shift in oncology's moral horizon, from the triumph of survival to the harder, longer work of living.
- Radiation and surgery save young lives, but they can quietly erode memory, attention, and emotional stability in the very brains they were meant to protect.
- Without a national system to detect these declines early, many Korean pediatric cancer survivors have been reaching adulthood with unaddressed impairments — often discovering the damage only when it is difficult to reverse.
- A $202 million Samsung-funded study across eight institutions is now tracking 106 children through every stage of treatment, catching cognitive and physical deterioration before it compounds.
- Early results show that 10–15% of patients exhibit measurable declines requiring intervention — and that timely referrals to rehabilitation are already producing meaningful improvements in individual cases.
- Korea's proton therapy infrastructure remains critically underdeveloped, and cognitive assessments are still excluded from national insurance coverage, leaving the study's gains dependent on philanthropic funding rather than systemic policy.
A child survives a brain tumor. The surgery works, the radiation works — and then the harder question begins. For decades, that question barely registered: when half of all pediatric brain tumor patients did not survive, survival itself was the only measure that mattered. But today, more than two-thirds of these children live. They grow up, go to school, and try to build lives — often discovering, slowly and sometimes too late, that the treatments that saved them have reshaped how their brains work.
Lee Joo-ho, a radiation oncology professor at Seoul National University Hospital, describes the shift plainly: medicine has entered an era where survival is no longer the final goal, but the beginning of a longer question about cognitive function, emotional stability, and independence. Since 2022, his team — spanning eight institutions including Samsung Medical Center and Yonsei Cancer Center — has been tracking 106 pediatric patients through detailed assessments before surgery, during radiation, and into their return to school. The research is made possible by a 300 billion won donation from the family of late Samsung Chairman Lee Kun-hee, directed toward pediatric cancer and rare disease research.
The study's premise is rooted in developmental urgency. Lee Jung, a child and adolescence psychiatry professor at Seoul National University Children's Hospital, notes that cognitive declines during childhood can amplify over time — and that Korea has lacked any systematic mechanism to catch them early enough for intervention to matter. This study changes that. When declines emerge, clinicians can act before the gaps widen.
So far, most of the 106 tracked patients have retained overall IQ scores. But 10 to 15 percent have shown measurable drops in processing speed, memory, attention, or physical strength — and received early intervention as a result. One girl with a normal IQ but deteriorating attention improved academically after medication. A boy anxious about his cognition was reassured by results showing above-average performance. The assessments became anchors for families navigating profound uncertainty.
Yet the study also illuminates what Korea still lacks. Cognitive evaluations remain outside national health insurance coverage, making the program dependent on philanthropic funding. Proton therapy — which better preserves healthy brain tissue during radiation — is available at only a handful of centers in the country. Experts argue that dedicated pediatric oncology facilities with advanced equipment and specialized staff are urgently needed. The data being gathered now may eventually support policy change — but that infrastructure has not yet arrived.
A child survives a brain tumor. The surgery works. The radiation works. The cancer is gone. And then the real question begins: what comes next?
For decades, that question barely mattered. When half of all children diagnosed with brain tumors did not live to see adulthood, survival itself was the only victory that counted. But medicine has shifted. Today, more than two-thirds of pediatric brain tumor patients survive. They grow up. They go to school. They try to build lives. And many of them discover, slowly and sometimes too late, that the treatments that saved them have also changed how their brains work.
Lee Joo-ho, a radiation oncology professor at Seoul National University Hospital, describes the transition plainly: "We've entered a new era where we contemplate how to improve patients' quality of life after their survival." The shift is not rhetorical. It is the difference between asking whether a child will live and asking whether that child will be able to think clearly, remember things, focus in school, move without pain, or live independently as an adult.
Since 2022, Lee and a research team spanning eight institutions—including Samsung Medical Center, the National Cancer Center, and Yonsei Cancer Center—have been tracking what happens to the brains of children undergoing treatment for these tumors. The study follows 106 pediatric patients through detailed cognitive, emotional, and physical assessments before surgery, during radiation therapy, and into their return to school. The work is funded by a 300 billion won donation (approximately $202 million) from the family of late Samsung Chairman Lee Kun-hee, directed toward pediatric cancer and rare disease research.
The data emerging from this tracking reveals a pattern that clinicians have long suspected but lacked the resources to document systematically. Radiation therapy, highly effective at destroying cancer cells, can also damage the developing brain. Children treated this way sometimes experience declines in memory, attention, and processing speed. They may struggle with emotional regulation. Their physical strength can diminish. International research shows that childhood cancer survivors face more than double the risk of failing to live independently as adults—a risk that climbs higher for those who received radiation.
What makes this study different is timing. Lee Jung, a child and adolescence psychiatry professor at Seoul National University Children's Hospital, explains why early detection matters: "Childhood and adolescence are critical periods for rapid brain development. Performance decline in cognitive capability during this time can amplify at later stages of growth." Korea, she notes, has lacked a system to catch these declines while intervention is still possible. The new study changes that. When problems emerge—and they often do subtly—clinicians can refer patients for rehabilitation before the gaps widen.
The results so far show the value of this approach. Among the 106 patients tracked through March, most retained overall intelligence quotient scores. But 10 to 15 percent showed measurable declines in processing speed, memory, attention, or physical strength that fell outside normal ranges. They received early intervention. In one case, a girl with normal IQ but deteriorating attention and learning speed improved academically after medication. A boy who feared his cognition had declined was reassured by test results showing above-average performance. The assessments functioned not only as diagnostic tools but as anchors for families navigating uncertainty.
Yet the study also exposed a gap in Korea's medical infrastructure. "We knew these evaluations were essential, but they were excluded from national health insurance coverage," Lee Joo-ho said. The Samsung donation made the testing, counseling, and feedback possible. Over time, he suggests, the accumulated data could become evidence supporting policy changes in insurance coverage and rehabilitation services. But more remains undone. Proton therapy—a form of radiation that better preserves healthy brain tissue—is considered key to protecting cognitive function in young patients, yet few centers in Korea offer it. Experts call for dedicated pediatric medical facilities with advanced equipment and specialized staff, a infrastructure investment that has not yet materialized.
Notable Quotes
We've entered a new era where we contemplate how to improve patients' quality of life after their survival.— Lee Joo-ho, radiation oncology professor at Seoul National University Hospital
Performance decline in cognitive capability during childhood and adolescence can amplify at later stages of growth.— Lee Jung, child and adolescence psychiatry professor at Seoul National University Children's Hospital
The Hearth Conversation Another angle on the story
Why does it matter that survival rates went from 50 percent to over 66 percent if the children still face cognitive problems afterward?
Because the problem used to be invisible. When most children didn't survive, no one studied what happened to those who did. Now we can actually see the damage and catch it early enough to help.
So the radiation that kills the cancer also damages the brain?
Yes, but not always in the same way or to the same degree. The study is mapping which brain regions are most vulnerable and how much exposure causes what kind of decline. That knowledge could eventually lead to better treatment strategies.
The article mentions that some signs are subtle. How do you even know if a child's cognition has declined?
You have to test them before treatment, during treatment, and after. Without those baseline measurements, you can't tell if a change is real or just normal variation. That's what Korea was missing—a system to track and compare.
What happens to the children who show impairment?
They get referred for rehabilitation. One girl in the study got medication that helped her attention and learning speed improve. Another boy was terrified he'd been permanently damaged, but testing showed he was actually fine. The reassurance itself matters.
Is this just a research project, or does it change how doctors treat these children now?
Both. The study is generating data that could eventually change policy and insurance coverage. But right now, it's also changing individual outcomes—clinicians can intervene earlier because they're monitoring continuously instead of waiting for problems to become obvious.
What's the biggest gap Korea still has?
Proton therapy centers. It's a more precise form of radiation that spares healthy brain tissue, but almost no hospitals in Korea offer it. And there are no dedicated pediatric cancer facilities with the specialized equipment and staff these children need.